enVVeno Medical Presents New Interim Venous Ulcer Healing Data From The VenoValve Pivotal Trial To Be Presented At VAM2024 Vascular Annual Meeting On June 21, 2024
Portfolio Pulse from Benzinga Newsdesk
enVVeno Medical Corporation (NASDAQ:NVNO) announced that new interim data from its VenoValve U.S. pivotal trial will be presented at the VAM2024 Vascular Annual Meeting on June 21, 2024. The data focuses on the impact of VenoValve implantation on venous ulcer healing in patients with deep venous reflux.
June 17, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
enVVeno Medical Corporation will present new interim data from its VenoValve U.S. pivotal trial at the VAM2024 Vascular Annual Meeting. This data could positively impact the stock price if the results are favorable.
The presentation of new interim data from the VenoValve trial at a major medical conference could generate positive attention and investor interest, potentially boosting the stock price if the data is favorable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100